Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy's Founder Dismisses Acquisition Talks As Gossip: "We Will Never Sell To An MNC"

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - "It's my life and we will never sell Dr. Reddy's to an MNC," Kallam Anji Reddy, who founded the nearly $2 billion Indian company 25 years ago, told a television news channel in an interview to quell widespread speculation that the firm is the target of multinational companies for a potential acquisition

You may also be interested in...



With Shrinking Market Share, GSK Sells Augmentin, Amoxil U.S. Rights To Dr. Reddy's, Along With Tennessee Manufacturing Site

MUMBAI - Acting on the strategy of hiving off late-stage brands and non-core assets, GlaxoSmithKline Pharma has sold its once marquee anti-bacterial Augmentin and Amoxil brand rights in the U.S. to India's Dr. Reddy's Labs for an undisclosed sum

With Shrinking Market Share, GSK Sells Augmentin, Amoxil U.S. Rights To Dr. Reddy's, Along With Tennessee Manufacturing Site

MUMBAI - Acting on the strategy of hiving off late-stage brands and non-core assets, GlaxoSmithKline Pharma has sold its once marquee anti-bacterial Augmentin and Amoxil brand rights in the U.S. to India's Dr. Reddy's Labs for an undisclosed sum

Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical

MUMBAI - Piramal Healthcare Chairman Ajay Piramal redefined the valuation processes for Indian life science companies last week, when he sold his domestic business of predominantly 350 branded generic products to Illinois-based Abbott for $3.72 billion - a jaw-dropping price that is nine times the level of annual sales and 31 times that of earnings

Related Content

UsernamePublicRestriction

Register

SC073353

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel